Abstract:In addition to providing a macromolecular scaffold, the extracellular matrix (ECM) is a critical regulator of cell function by virtue of specific physical, biochemical, and mechanical properties. Collagen is the main ECM component and hence plays an essential role in the pathogenesis and progression of chronic lung disease. It is well-established that many chronic lung diseases, e.g., chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF) primarily manifest in the elderly, suggesting increased susceptibility of the aged lung or accumulated alterations in lung structure over time that favour disease. Here, we review the main steps of collagen biosynthesis, processing, and turnover and summarise what is currently known about alterations upon lung ageing, including changes in collagen composition, modification, and crosslinking. Recent proteomic data on mouse lung ageing indicates that, while the ER-resident machinery of collagen biosynthesis, modification and triple helix formation appears largely unchanged, there are specific changes in levels of type IV and type VI as well as the two fibril-associated collagens with interrupted triple helices (FACIT), namely type XIV and type XVI collagens. In addition, levels of the extracellular collagen crosslinking enzyme lysyl oxidase are decreased, indicating less enzymatically mediated collagen crosslinking upon ageing. The latter contrasts with the ageing-associated increase in collagen crosslinking by advanced glycation endproducts (AGEs), a result of spontaneous reactions of protein amino groups with reactive carbonyls, e.g., from monosaccharides or reactive dicarbonyls like methylglyoxal. Given the slow turnover of extracellular collagen such modifications accumulate even more in ageing tissues. In summary, the collective evidence points mainly toward age-induced alterations in collagen composition and drastic changes in the molecular nature of collagen crosslinks. Future work addressing the consequences of these changes may provide important clues for prevention of lung disease and for lung bioengineering and ultimately pave the way to novel targeted approaches in lung regenerative medicine.

Regulation of cellular senescence by extracellular matrix during chronic fibrotic diseases

Regulation of Cellular Senescence Is Independent from Profibrotic Fibroblast-Deposited ECM

The aged extracellular matrix and the profibrotic role of senescence-associated secretory phenotype

The ECM path of senescence in aging: components and modifiers

The potential role of senescence in limiting fibrosis caused by aging

Impaired angiogenesis in ageing: the central role of the extracellular matrix

Longevity-Promoting Pathways and Transcription Factors Respond to and Control Extracellular Matrix Dynamics During Aging and Disease

Collagen Biosynthesis, Processing, and Maturation in Lung Ageing

Chronic lung diseases: entangled in extracellular matrix

Extracellular matrix regulation of fibroblast function: redefining our perspective on skin aging

Senescence and tissue fibrosis: opportunities for therapeutic targeting

Age-Related Changes in Extracellular Matrix

Extracellular matrix endocytosis in controlling matrix turnover and beyond: emerging roles in cancer.

Substrate stiffness engineered to replicate disease conditions influence senescence and fibrotic responses in primary lung fibroblasts

Nε-Carboxymethyl-Lysine Modification of Extracellular Matrix Proteins Augments Fibroblast Activation

Cellular Senescence in Kidney Fibrosis: Pathologic Significance and Therapeutic Strategies

The Extracellular Matrix: Its Composition, Function, Remodeling, and Role in Tumorigenesis

Aged Skeletal Muscle Retains the Ability to Remodel Extracellular Matrix for Degradation of Collagen Deposition after Muscle Injury

Cell Senescence-Independent Changes of Human Skin Fibroblasts with Age

Novel insights into the function and dynamics of extracellular matrix in liver fibrosis

Targeting Senescent Cells in Fibrosis: Pathology, Paradox, and Practical Considerations